25 Jul 2017 --- Intralytix has received US$17.5 million in new equity funding from Lesaffre, a French family group. This investment marks the beginning of a close collaboration between both companies to develop and commercialize bacteriophage-based products, for various benefits in human health and in other areas of mutual interest. The size of Lesaffre’s stake in Intralytix as a result of this investment was not disclosed.
